Lapatinib and Cetuximab in Patients With Solid Tumors

Exclusion Criteria

• •Chemotherapy or surgery within 4 weeks prior to treatment start
• •Radiation treatment within 3 weeks prior to treatment start
• •Prior therapy with lapatinib
• •Untreated brain metastasis or neurologically unstable CNS metastases
• •Any severe or uncontrolled medical condition or other condition that could affect participation in this study including unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction \</= 6 months prior to study entry
• •Diarrhea \> grade 1 at baseline
• •Patients on a medication or herbal therapy known to inhibit CYP3A4
• •Gastrointestinal tract disease resulting in the inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption or active peptic ulcer disease
• •Ongoing ventricular cardiac dysrhythmias of grade \>/= 2
• •Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation \>= 3 beats in a row)
• •Serious cardiac arrhythmia requiring medication
• •QTc interval \> 500 msec
• •Female patients who are pregnant or breast feeding, or adults who are of reproductive potential and are unwilling to refrain from conceiving a child during study treatment
• •Patients unwilling or unable to comply with the protocol or provide informed consent